Wall Street analysts forecast that Trevena Inc (NASDAQ:TRVN) will report earnings of ($0.19) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Trevena’s earnings, with the highest EPS estimate coming in at ($0.18) and the lowest estimate coming in at ($0.21). Trevena posted earnings per share of ($0.36) during the same quarter last year, which indicates a positive year over year growth rate of 47.2%. The business is expected to issue its next quarterly earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Trevena will report full year earnings of ($0.89) per share for the current year, with EPS estimates ranging from ($1.17) to ($0.73). For the next financial year, analysts anticipate that the business will post earnings of ($0.70) per share, with EPS estimates ranging from ($1.22) to ($0.41). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Trevena.
Trevena (NASDAQ:TRVN) last released its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.02.
Several equities analysts have commented on the stock. Oppenheimer set a $5.00 price target on shares of Trevena and gave the company a “buy” rating in a research note on Monday, March 12th. HC Wainwright increased their price target on shares of Trevena to $7.00 and gave the company a “buy” rating in a research note on Thursday, March 8th. Finally, Zacks Investment Research lowered shares of Trevena from a “buy” rating to a “hold” rating and set a $2.00 price target on the stock. in a research note on Saturday, January 20th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $7.06.
Shares of TRVN stock traded down $0.03 during trading hours on Friday, reaching $1.63. 815,034 shares of the stock were exchanged, compared to its average volume of 876,465. The firm has a market capitalization of $107.12, a price-to-earnings ratio of -1.35 and a beta of -0.52. Trevena has a 12-month low of $1.34 and a 12-month high of $3.64. The company has a debt-to-equity ratio of 0.45, a quick ratio of 3.71 and a current ratio of 3.71.
Institutional investors have recently made changes to their positions in the business. American Century Companies Inc. purchased a new position in Trevena in the fourth quarter valued at approximately $135,000. Dimensional Fund Advisors LP grew its position in shares of Trevena by 37.8% during the third quarter. Dimensional Fund Advisors LP now owns 980,440 shares of the biopharmaceutical company’s stock worth $2,500,000 after acquiring an additional 268,825 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Trevena by 15.0% during the second quarter. Vanguard Group Inc. now owns 1,822,103 shares of the biopharmaceutical company’s stock worth $4,191,000 after acquiring an additional 238,089 shares during the last quarter. Bourgeon Capital Management LLC grew its position in shares of Trevena by 59.3% during the fourth quarter. Bourgeon Capital Management LLC now owns 137,800 shares of the biopharmaceutical company’s stock worth $220,000 after acquiring an additional 51,300 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of Trevena by 15.8% during the second quarter. Northern Trust Corp now owns 572,662 shares of the biopharmaceutical company’s stock worth $1,318,000 after acquiring an additional 77,934 shares during the last quarter. Institutional investors own 50.47% of the company’s stock.
Trevena Company Profile
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.